Patents by Inventor Jonathan Goke

Jonathan Goke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of predicting for benefit from immune checkpoint inhibition therapy
    Patent number: 12680137
    Abstract: The present invention relates to a method of identifying a patient suffering from cancer as benefiting or not benefiting from immune checkpoint inhibition therapy comprising the steps of measuring an expression level of one or more preselected markers in a cancerous biological sample obtained from the patient, identifying a differentially expressed alternative promoter based on the expression level of the one or more preselected markers, calculating an alternative promoter usage score and identifying the patient as benefiting or not benefiting from immune checkpoint inhibition therapy using the alternative promoter usage score. The present invention also relates to a biomarker for excluding a patient suffering from cancer from immune checkpoint inhibition therapy.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 14, 2026
    Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Patrick Tan, Raghav Sundar, Kie Kyon Huang, Aditi Qamra, Jonathan Goke, Deniz Demircioglu
  • METHOD OF PREDICTING FOR BENEFIT FROM IMMUNE CHECKPOINT INHIBITION THERAPY
    Publication number: 20220081723
    Abstract: The present invention relates to a method of identifying a patient suffering from cancer as benefiting or not benefiting from immune checkpoint inhibition therapy comprising the steps of measuring an expression level of one or more preselected markers in a cancerous biological sample obtained from the patient, identifying a differentially expressed alternative promoter based on the expression level of the one or more preselected markers, calculating an alternative promoter usage score and identifying the patient as benefiting or not benefiting from immune checkpoint inhibition therapy using the alternative promoter usage score. The present invention also relates to a biomarker for excluding a patient suffering from cancer from immune checkpoint inhibition therapy.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 17, 2022
    Inventors: Patrick Tan, Raghav Sundar, Kie Kyon Huang, Aditi Qamra, Jonathan Goke, Deniz Demircioglu